Aptose Biosciences (TSE:APS) Stock Passes Above Fifty Day Moving Average – What’s Next?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$2.03 and traded as high as C$2.31. Aptose Biosciences shares last traded at C$2.15, with a volume of 3,833 shares traded.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners lowered Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, Aptose Biosciences has an average rating of “Hold”.

Aptose Biosciences Trading Down 3.6%

The stock has a market capitalization of C$5.49 million, a P/E ratio of 3.12 and a beta of -0.41. The stock’s fifty day moving average price is C$2.03 and its 200 day moving average price is C$1.87. The company has a debt-to-equity ratio of -117.37, a current ratio of 1.05 and a quick ratio of 5.41.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share for the quarter. Research analysts forecast that Aptose Biosciences Inc. will post -0.59 earnings per share for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.